Content area
Abstract
The senior leadership team of Scientus will consist of Har Grover (Executive Chairman), Trevor Folk (Chief Executive Officer), Rav Grover (Chief Financial Officer) and Phil Hemans (Chief Commercial Officer). The merger results in a vertically-integrated biopharmaceutical Licensed Dealer under the Controlled Drug Substance Act (CDSA) and specifically the Narcotics Control Regulations (NCR) of Canada with a focus on developing and commercializing pharmaceutical-grade cannabinoid derivative products. Notable benefits of the Business Combination include: --__creation of a vertically-integrated biopharmaceutical Licensed Dealer ____with approvals under the Controlled Drug Substance Act (CDSA), the ____Narcotics Control Regulations (NCR) of Canada and Access to Cannabis for ____Medical Purposes Regulations (ACMPR); --__a 45,000-square foot GMP-compliant facility located in Whitby, Ontario; --__regulatory approval permitting the extraction of Cannabis Resin used to ____produce formulations and products for domestic and international ____markets; --__ACMPR Licensed Producer application to cultivate up to 6,000kg per year, ____which is in the final review stage of the application and licensing ____process; --__state-of-the-art R&D laboratory facilities; --__best-in-class proprietary technology and methods to manufacture ____cannabinoid extracts (Patent Pending) which allows Scientus to produce ____continuous, consistent batch profiles, a prerequisite to formulating ____pharma-grade derivative products targeting the human endocannabinoid ____system; --__a strong IP driven business model with a...